WEO CRC SC Meeting. Vienna, Austria October 14, 2016

Size: px
Start display at page:

Download "WEO CRC SC Meeting. Vienna, Austria October 14, 2016"

Transcription

1 WEO CRC SC Meeting Vienna, Austria October 14, 216

2 Possibleconflictsofinterest The Bowel Health Service receives material support from Eiken Chemical Company. Erin Symonds

3 FIT positivity rate is highest in the people who participate in the first week after receiving the kit Observations from a South Australian screening program Erin Symonds Graeme Young Bowel Health Service, Repatriation General Hospital Flinders Centre for Innovation in Cancer AUSTRALIA

4 FOBT participation rates around the world Higher participation found with: Females Older age Subsequent screening rounds Blom J et al J Med Screen 214 Higher socioeconomic status Von Wagner et al Int J Epidemiol 211 Higher level of education Frederiksen BL et al Br J Cancer 21 No effect of family history of CRC Perencevich M, et al Gastroenterol 213 % 1% 2% 3% 4% % 6% 7% 8% Klabunde, et al J Med Screen 21 Most <% participation

5 Aim To establish FIT participation and positivity profiles and predictors. Population A hospital based screening and surveillance program for people at higher risk for CRC. 2 sample FITs (OC Sensor) have been used since Aug 28. Total of 36,331 FITs sent. Positive FIT = one sample 2μg Hb/g faeces. All samples are analysed within two weeks of sample collection Erin Symonds

6 FIT participation in a higher risk population 3 2 FIT participation (%) Reminder letter wk 1 (n=3421) wk 2 (n=698) wk 3 (n=328) wk 4 (n=244) wk (n=147) wk 6 (n=183) wk 7 (n=1491) wk 8 (n=1) wk 9 (n=94) Participation in the hospital program is 6.% (higher than National program participation of 37%) 9% of the people who are going to participate do so in the first 9 weeks

7 FIT participation PREDICTORS FOR PARTICIPATION IN A HIGHER RISK POPULATION Female Older age Higher SES Previous FIT rounds (same as average risk population) Factor OR (9% CI) P value Female (compared to male) 1.23 ( ) <.1 Age (compared to <y) -6y 1.76 ( ) <.1 6-7y 3.4 ( ) < ( ) <.1 Socioeconomic status (compared to highest quintile) 2 nd highest.99 ( ).69 Middle.93 ( ).44 2 nd lowest.91 ( ).4 lowest.8 ( ) <.1 Subsequent FIT offer (compared to 1 st offer) 1.9 (.8-.67) <.1

8 FIT participation (%) FIT positivity rate Participation Reminder letter wk 1 wk 2 wk 3 wk 4 wk wk 6 wk 7 wk 8 wk 9 FIT positivity (%) % of samples with Hb 2µg/g faeces Reminder letter wk 1 wk 2 wk 3 wk 4 wk wk 6 wk 7 wk 8 wk 9 Greatest FIT positivity with samples returned week 1 in the higher risk population

9 Positivity rate: average risk population 4 Participation 12 % of samples with Hb 2µg/g faeces % particiaptino Reminder letter FIT positivity (%) Reminder letter Same observations in an average risk population, with greatest positivity in the first week of returns.

10 Risk factors for positivity Variables associated with positivity High Hb levels Rectal bleeding Cancer and adenomas Male Socioeconomic status Older age

11 Early positives due to symptoms? Are these samples associated with people noticing bleeding? (multivariate OR.36 (9%CI )) Will there be a higher Hb level? NO 7 Median Hb of positive samples 2 Proportion of samples with Hb 2µg/g faeces Median Hb (ug/ug) wk 1 wk 2 wk 3 wk 4 wk wk 6 wk 7 wk 8 wk 9 % of positive samples with a high Hb (>2ug/g) wk 1 wk 2 wk 3 wk 4 wk wk 6 wk 7 wk 8 wk 9

12 Early positives due to symptoms? Will these samples have a higher positive predictive value for neoplasia? 2 OR 1.13 (9% CI: ) Positive predictive value (%) significant adenoma Cancer wk 1 (n=249) wk 2 (n=369) wk 3 (n=22) wk 4 (n=118) wk (n=86) wk 6 (n=66) wk 7 (n=14) wk 8 (n=1) wk 9 (n=41)

13 Early positives due to demographic differences with participation? Male gender Lower socioeconomic status Older age All linked to increased positivity risk FIT participation (%) No significant differences male female FIT participation (%) No significant differences highest SES 2nd highest middle 2nd lowest lowest SES wk 1 wk 2 wk 3 wk 4 wk wk 6 wk 7 wk 8 wk 9 wk 1 wk 2 wk 3 wk 4 wk wk 6 wk 7 wk 8 wk 9

14 Early positives due to demographic differences with participation? Male gender Lower socioeconomic status Older age 3 3 Odds ratio of having an early positive FIT result Factor OR (9% CI) P value Age (compared to <y) -6y.69 (.32-1.) >. 6-7y 1.4 ( ) >. 7+ y 2.46 ( ).19 participation (%) wk 1 wk 2 wk 3 wk 4 wk wk 6 wk 7 wk 8 wk 9 <y -9y 6-69y >=7y Earliest participation in the 7+ age group

15 Conclusions Participation Predictors for FIT participation are the same in a higher risk population compared to average risk populations. Positivity Highest returns of positive FITs week 1 and again after reminder letters. This is most likely due to the older age group participating early and being at higher risk for a positive result An early returned positive FIT does not indicate increased risk for neoplasia and can not be used to triage for colonoscopy.

16 ACKNOWLEDGEMENTS Repatriation General Hospital Steve Cole Graeme Young Robert Fraser Charles Cock Gretchen Jean Kalindra Simpson Michelle Coats Susan Wick Jo Osborne Dawn Bastin Flinders Medical Centre Peter Bampton Karen Saxty Jayne Sandford Angela Chaplin Tennyson Centre Lyn Williams Noarlunga Centre Dawn Cotterill

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015 WEO CRC SC Meeting Barcelona, Spain October 23, 2015 THE HEMOGLOBIN CONCENTRATION IN A NEGATIVE RESULT AS A PREDICTOR FOR ADVANCED NEOPLASIA Isabel Portillo, Eunare Arana-Arri, Isabel Idigoras, Lorea Martínez-Indart.

More information

NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report.

NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report. NHS Bowel Cancer Screening Programmes: Evaluation of pilot of Faecal Immunochemical Test : Final report. Sue Moss, Christopher Mathews Centre for Cancer Prevention, Wolfson Institute, Queen Mary University

More information

Haemoglobin level at previous negative FIT and risk of neoplasia at subsequent screening rounds. Carlo SENORE

Haemoglobin level at previous negative FIT and risk of neoplasia at subsequent screening rounds. Carlo SENORE Haemoglobin level at previous negative FIT and risk of neoplasia at subsequent screening rounds Carlo SENORE Possible conflicts of interest None related to the presentation Carlo Senore AIMS To estimate

More information

Prof Stephen P. Halloran. Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT

Prof Stephen P. Halloran. Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT Prof Stephen P. Halloran Update on the NHS Bowel Cancer Screening Programme Focus on BS & FIT World Top 20 Cancers Men Incidence & Mortality (2012) Women World Colorectal Cancer 3 rd commonest cancer 4

More information

Friday, 23 October 2015: 10:15 12:00 * * * * *

Friday, 23 October 2015: 10:15 12:00 * * * * * Barcelona 2015 8 th Meeting of the Expert Working Group (EWG) FIT for Screening Expert Working Group (EWG) founding members: Friday, 23 October 2015: 10:15 12:00 MEETING REPORT * * * * * Jim Allison, University

More information

Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University WCC, Melbourne

Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University WCC, Melbourne Global colorectal cancer screening appropriate or practical? Graeme P Young, Flinders University. 2014 WCC, Melbourne Outline WHO criteria to justify screening Appropriateness: Global variation in incidence

More information

Colorectal cancer screening in England

Colorectal cancer screening in England Colorectal cancer screening in England critical analysis Prof Stephen P. Halloran Participation Rate 57% All Screens (1.9% +ve) 52% Prevalent 1 st Screen (age 60 years) 36% Prevalent Screen (2.2% +ve)

More information

Risk scoring incorporating FIT in triage of symptomatic patients

Risk scoring incorporating FIT in triage of symptomatic patients Risk scoring incorporating FIT in triage of symptomatic patients Centre for Research into Cancer Prevention and Screening University of Dundee Scotland Possible conflicts of interest None Background Symptoms

More information

The Dutch bowel cancer screening program Relevant lessions for Ontario

The Dutch bowel cancer screening program Relevant lessions for Ontario The Dutch bowel cancer screening program Relevant lessions for Ontario Ernst J Kuipers Erasmus MC University Medical Center Rotterdam - The Netherlands 1 Ismar Boas (1858 1938) Colorectal cancer screening

More information

The National Bowel Cancer Screening Program

The National Bowel Cancer Screening Program research Amanda Bobridge Steve Cole Mark Schoeman Helen Lewis Peter Bampton Graeme Young The National Bowel Cancer Screening Program Consequences for practice Background The Australian Government introduced

More information

Comparison of FIT performance in screening programs. Carlo Senore

Comparison of FIT performance in screening programs. Carlo Senore Comparison of FIT performance in screening programs Possible conflicts of interest None related to the presentation Background Several FIT kits are now available Various FIT brands use a variety of sampling

More information

North West London Pathology. Faecal Occult Blood testing. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist

North West London Pathology. Faecal Occult Blood testing. Mrs Sophie Barnes FRCPath Consultant Clinical Scientist Faecal Occult Blood testing Mrs Sophie Barnes FRCPath Consultant Clinical Scientist Learning objectives Background Guidelines for colorectal cancer detection Tests available to detect occult blood in faeces

More information

Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients

Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients Faecal Immunochemical Testing (FIT) for Screening and Symptomatic Patients Caroline Addison NE BCSP Hub Director and Consultant Clinical Scientist What is FIT Type of Faecal Occult Blood test Designed

More information

Implementing of Population-based FOBT Screening

Implementing of Population-based FOBT Screening Implementing of Population-based FOBT Screening gfobt to FIT Experience from England Prof Stephen P. Halloran Guaiac FOBt Haem 2H 2 O 2 = 2H 2 0 + O 2 Oxidised guaiaconic acid is blue Biennial Bowel Cancer

More information

FIT Overview. Objectives 6/23/2014

FIT Overview. Objectives 6/23/2014 ADDS 2014: Plenary 2 FIT Update Clarence Wong, MD FRCPC Associate Professor of Medicine, University of Alberta Provincial Medical Lead, Alberta Colorectal Cancer Screening Program 1 Objectives After this

More information

Interval Fecal Immunochemical Testing in a Colonoscopic Surveillance Program Speeds Detection of Colorectal Neoplasia

Interval Fecal Immunochemical Testing in a Colonoscopic Surveillance Program Speeds Detection of Colorectal Neoplasia GASTROENTEROLOGY 2010;139:1918 1926 Interval Fecal Immunochemical Testing in a Colonoscopic Surveillance Program Speeds Detection of Colorectal Neoplasia JOANNE M. LANE,*, ELIZABETH CHOW,*, GRAEME P. YOUNG,*,

More information

Results from 2.6 million invitations between : 54% overall uptake (von Wagner et al., 2011)

Results from 2.6 million invitations between : 54% overall uptake (von Wagner et al., 2011) TRICCS: Text-message Reminders in Colorectal Cancer Screening Research Department of Behavioural Science and Health University College London Christian von Wagner (c.wagner@ucl.ac.uk ) Background Colorectal

More information

Bowel Cancer Screening Exploiting science brings better medicine

Bowel Cancer Screening Exploiting science brings better medicine Camberley & District Bowel Cancer Screening Exploiting science brings better medicine Prof Stephen P. Halloran World - All Cancers Men Incidence & Mortality (2012) Women Incidence Mortality GLOBOCAN 2012

More information

An Update on the Bowel Cancer Screening Programme. Natasha Djedovic, London Hub Director 17 th September 2018

An Update on the Bowel Cancer Screening Programme. Natasha Djedovic, London Hub Director 17 th September 2018 An Update on the Bowel Cancer Screening Programme Natasha Djedovic, London Hub Director 17 th September 2018 NHS Bowel Cancer Screening Programme 2006: 60-69 yr old men & women offered guaiac Faecal Occult

More information

Friday, 17 October 2014: 08:30 11:30 * * * * *

Friday, 17 October 2014: 08:30 11:30 * * * * * Vienna 2014 6 th Meeting of the Expert Working Group (EWG) FIT for Screening Expert Working Group (EWG) founding members: Friday, 17 October 2014: 08:30 11:30 MEETING REPORT * * * * * Jim Allison, University

More information

FIT for purpose: enhanced applications for faecal immunochemical tests

FIT for purpose: enhanced applications for faecal immunochemical tests Review Article Page 1 of 11 FIT for purpose: enhanced applications for faecal immunochemical tests Erin L. Symonds 1,2, Robert J. L. Fraser 3, Graeme P. Young 2 1 Bowel Health Service, Flinders Medical

More information

PUBLISHED VERSION.

PUBLISHED VERSION. PUBLISHED VERSION Amy Duncan, Deborah Turnbull, Carlene Wilson, Joanne M. Osborne, Stephen R. Cole, Ingrid Flight, Graeme P. Young Behavioural and demographic predictors of adherence to three consecutive

More information

Bowel Cancer Prevention and Screening. Harriet Wynne, Cancer Council Victoria

Bowel Cancer Prevention and Screening. Harriet Wynne, Cancer Council Victoria Bowel Cancer Prevention and Screening Harriet Wynne, Cancer Council Victoria New cases and deaths for the Victoria population in 2013 Thursfield V, et al. Cancer in Victoria: Statistics & trends 2013.

More information

Screening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee

Screening for GI Cancer Past Present and Future. Prof. Bob Steele University of Dundee Screening for GI Cancer Past Present and Future Prof. Bob Steele University of Dundee Worldwide Cancer Incidence Rates UK Cancer Incidence Rates Screening The detection of disease in asymptomatic subjects

More information

Improving Access to Endoscopy at Safety-Net Hospitals. Lukejohn W. Day MD Assistant Professor of Medicine

Improving Access to Endoscopy at Safety-Net Hospitals. Lukejohn W. Day MD Assistant Professor of Medicine Improving Access to Endoscopy at Safety-Net Hospitals Lukejohn W. Day MD Assistant Professor of Medicine Goals Background Improving Access to Endoscopic Care Electronic referral: ereferral Direct Access

More information

Colorectal Cancer Screening in Ohio CHCs. Ohio Association of Community Health Centers

Colorectal Cancer Screening in Ohio CHCs. Ohio Association of Community Health Centers Colorectal Cancer Screening in Ohio CHCs Ohio Association of Community Health Centers 2 1/29/2015 Your Speakers Dr. Ted Wymyslo Ashley Ballard Randy Runyon 3 1/29/2015 Facts 3 rd most common cancer in

More information

Why FIT (Faecal Immunochemical Test) is the best biomarker for CRC screening

Why FIT (Faecal Immunochemical Test) is the best biomarker for CRC screening Why FIT (Faecal Immunochemical Test) is the best biomarker for CRC screening Prof. Stephen Halloran Royal Surrey County Hospital NHS Cancer Screening Programme University of Surrey gfobt Guaiacum Officinale

More information

Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech MUDr.. Petr Kocna, CSc.

Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech MUDr.. Petr Kocna, CSc. Quantitative immunochemical tests: evidence on accuracy and implementation considerations in the Czech MUDr.. Petr Kocna, CSc. European Digestive Cancer Days, Prague - 26. September 2017 QUANTITATIVE FIT

More information

University of Dundee. Published in: Journal of Medical Screening DOI: / Publication date: 2016

University of Dundee. Published in: Journal of Medical Screening DOI: / Publication date: 2016 University of Dundee Interval cancers using a quantitative faecal immunochemical test (FIT) for haemoglobin when colonoscopy capacity is limited Digby, Jayne; Fraser, Callum G.; Carey, Francis A.; Lang,

More information

National Colonoscopy Study (NCS) Screening Colonoscopy versus Annual Fecal Occult Blood Test NCT

National Colonoscopy Study (NCS) Screening Colonoscopy versus Annual Fecal Occult Blood Test NCT National Colonoscopy Study (NCS) Screening Colonoscopy versus Annual Fecal Occult Blood Test NCT 00102011 Ann Zauber Sidney Winawer, Michael O Brien, John Allen, Andrew Feld, Glenn Mills, Robin Mendelsohn,

More information

Challenges for Colorectal Cancer Screening

Challenges for Colorectal Cancer Screening Challenges for Colorectal Cancer Screening a Biomarker with No Standards! Prof. Emeritus Stephen P. Halloran University of Surrey W. Europe Top 20 Cancers Men Incidence & Mortality (2012) Women World -

More information

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015

WEO CRC SC Meeting. Barcelona, Spain October 23, 2015 WEO CRC SC Meeting Barcelona, Spain October 23, 2015 Identification of serrated polyposis syndrome in the context of population-based CRC screening programs Evelien Dekker Academic Medical Center Amsterdam,

More information

FIT - A Tale of Two Settings. Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland

FIT - A Tale of Two Settings. Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland FIT - A Tale of Two Settings Callum G Fraser Centre for Research into Cancer Prevention and Screening University of Dundee Scotland Possible Conflicts of Interest Consultant: Kyowa, Tokyo, Japan Consultant:

More information

Friday, 15 May 2015: 10:00 12:00 * * * * *

Friday, 15 May 2015: 10:00 12:00 * * * * * Washington 2015 7 th Meeting of the Expert Working Group (EWG) FIT for Screening Friday, 15 May 2015: 10:00 12:00 MEETING REPORT * * * * * Expert Working Group (EWG) founding members: Jim Allison, University

More information

Diagnostics guidance Published: 26 July 2017 nice.org.uk/guidance/dg30

Diagnostics guidance Published: 26 July 2017 nice.org.uk/guidance/dg30 Quantitative faecal immunochemical tests to guide referral for colorectal cancer in primary care Diagnostics guidance Published: 26 July 2017 nice.org.uk/guidance/dg30 NICE 2018. All rights reserved. Subject

More information

A TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE. Stool DNA test

A TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE. Stool DNA test A TEST FOR COLORECTAL CANCER THAT IS 92% SENSITIVE AND NON-INVASIVE Stool DNA test THE NEW NON-INVASIVE SCREENING TEST FOR COLORECTAL CANCER Sensitive Clinically proven 1 Easy to use FDA approved COLOGUARD

More information

Bowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care

Bowel cancer risk in the under 50s. Greg Rubin Professor of General Practice and Primary Care Bowel cancer risk in the under 50s Greg Rubin Professor of General Practice and Primary Care Prevalence of GI problems in the consulting population Thompson et al, Gut 2000 Number of patients % of patients

More information

The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean?

The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean? The New Grade A: USPSTF Updated Colorectal Cancer Screening Guidelines, What does it all mean? Robert A. Smith, PhD Cancer Control, Department of Prevention and Early Detection American Cancer Society

More information

(Bowel) Cancer Screening an update. Mike Hulme-Moir Colorectal Surgeon CD NZ Bowel Screening Pilot

(Bowel) Cancer Screening an update. Mike Hulme-Moir Colorectal Surgeon CD NZ Bowel Screening Pilot (Bowel) Cancer Screening an update Mike Hulme-Moir Colorectal Surgeon CD NZ Bowel Screening Pilot Screening The application of tests, examinations or other procedures. to sort out apparently well persons

More information

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population

Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population Latest Endoscopic Guidelines for FAP, HNPCC, IBD, and the General Population David T. Rubin, M.D. Assistant Professor of Medicine Inflammatory Bowel Disease Center MacLean Center for Clinical Medical Ethics

More information

Optimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial

Optimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial Optimizing implementation of fecal immunochemical testing in Ontario: A randomized controlled trial J. Tinmouth, N.N. Baxter, L.F. Paszat, E. Randell, M. Serenity, R. Sutradhar, L. Rabeneck Conflicts of

More information

Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative

Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative Debate: General surveillance/screening for colon cancer in a resource constrained environment is imperative Dr. Meryl Oyomno Department of surgery, University of Pretoria INTRODUCTION Screening is the

More information

What I ll discuss. Head to Head Comparisons of Different FITs. What makes a FIT good? What makes a good FIT? Good performance

What I ll discuss. Head to Head Comparisons of Different FITs. What makes a FIT good? What makes a good FIT? Good performance WEO SC EWG FIT for Screening Head to Head Comparisons of Different FITs Thomas F. Imperiale, MD Indiana University Medical Center WEO SC DDW San Diego, CA May 20, 2016 What I ll discuss Technical / clinical

More information

Faecal testing in colorectal cancer screening: State of the Art. Prof Stephen P. Halloran

Faecal testing in colorectal cancer screening: State of the Art. Prof Stephen P. Halloran Faecal testing in colorectal cancer screening: State of the Art Prof Stephen P. Halloran Faecal Immunochemical Test (FIT) gfobt Globin (Human) Haem Guaiac test gfobt Study Cohort 10,011 L Hol et al Gut

More information

Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer

Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer Guidelines for Colonoscopy Surveillance After Screening and Polypectomy: A Consensus Update by the US Multi-Society Task Force on Colorectal Cancer David A. Lieberman, 1 Douglas K. Rex, 2 Sidney J. Winawer,

More information

Northern Ireland Bowel Cancer Screening Programme. Pathways. Version 4 1 st October 2013

Northern Ireland Bowel Cancer Screening Programme. Pathways. Version 4 1 st October 2013 Northern Ireland Bowel Cancer Screening Programme Pathways These changes will be version controlled, led by the Quality Assurance Director for the Programme. Any updated versions will be circulated and

More information

RESEARCH. Abstract. Corresponding Author: Dr Sara Javanparast Discipline of Public Health Flinders University

RESEARCH. Abstract. Corresponding Author: Dr Sara Javanparast Discipline of Public Health Flinders University A cross-sectional analysis of participation in National Bowel Cancer Screening Program in Adelaide by age, gender and geographical location of residence. Sara Javanparast 1, Paul R Ward 1, Stephen Cole

More information

Performance targets for lesion detection in surveillance

Performance targets for lesion detection in surveillance Performance targets for lesion detection in surveillance WEO CRC Meeting 2018, Washington DC Uri Ladabaum, M.D., M.S. Professor of Medicine; Director, GI Cancer Prevention Division of Gastroenterology

More information

University of Dundee. Published in: Annals of Clinical Biochemistry DOI: / Publication date: 2017

University of Dundee. Published in: Annals of Clinical Biochemistry DOI: / Publication date: 2017 University of Dundee Application of NICE guideline NG12 to the initial assessment of patients with lower gastrointestinal symptoms Quyn, Aaron J.; Steele, Robert; Digby, Jayne; Strachan, Judith A.; Mowat,

More information

TPMG experience in improving colorectal cancer screening rates

TPMG experience in improving colorectal cancer screening rates TPMG experience in improving colorectal cancer screening rates Theodore R. Levin, MD Clinical Lead for CRC screening, The Permanente Medical Group, Inc Kaiser Permanente Northern California Kaiser Permanente

More information

Improving adherence to colorectal cancer surveillance guidelines: results of a randomised controlled trial

Improving adherence to colorectal cancer surveillance guidelines: results of a randomised controlled trial Carey et al. BMC Cancer (2017) 17:106 DOI 10.1186/s12885-017-3095-x RESEARCH ARTICLE Open Access Improving adherence to colorectal cancer surveillance guidelines: results of a randomised controlled trial

More information

Cost-effectiveness of adenoma surveillance - the Dutch guidelines -

Cost-effectiveness of adenoma surveillance - the Dutch guidelines - Cost-effectiveness of adenoma surveillance - the Dutch guidelines - WEO working group adenoma surveillance 20 May, 2016 Iris Lansdorp-Vogelaar, PhD On behalf of the SAP study-group Introduction Adenoma

More information

Bowel cancer screening and prevention

Bowel cancer screening and prevention Bowel cancer screening and prevention Cancer Incidence and Mortality Victoria 2012 Number 6000 5000 4000 3000 2000 Incidences = 29,387 Mortality = 10,780 Incidence Mortality 1000 0 Prostate Breast Bowel

More information

Practical challenges in establishing and running the Czech national colorectal cancer screening programme

Practical challenges in establishing and running the Czech national colorectal cancer screening programme Ústřední vojenská nemocnice - Vojenská fakultní nemocnice Praha 1. lékařská fakulta Univerzity Karlovy Interní klinika Practical challenges in establishing and running the Czech national colorectal cancer

More information

Risk assessment tools for the symptomatic population Graham Radford-Smith Department of Gastroenterology and Hepatology Royal Brisbane and Women s

Risk assessment tools for the symptomatic population Graham Radford-Smith Department of Gastroenterology and Hepatology Royal Brisbane and Women s Risk assessment tools for the symptomatic population Graham Radford-Smith Department of Gastroenterology and Hepatology Royal Brisbane and Women s Hospital GI inflammation IBD Group QIMR Berghofer Medical

More information

Development and evaluation of a risk assessment tool to improve clinical triage accuracy for colonoscopic investigations

Development and evaluation of a risk assessment tool to improve clinical triage accuracy for colonoscopic investigations Lord et al. BMC Cancer (2018) 18:229 https://doi.org/10.1186/s12885-018-4140-0 RESEARCH ARTICLE Development and evaluation of a risk assessment tool to improve clinical triage accuracy for colonoscopic

More information

Screening for Colorectal Cancer in the Elderly. The Broad Perspective

Screening for Colorectal Cancer in the Elderly. The Broad Perspective Screening for Colorectal Cancer in the Elderly Charles J. Kahi, MD, MSCR Indiana University School of Medicine Richard L. Roudebush VA Medical Center Indianapolis, Indiana ACG Regional Midwest Course Symposium

More information

Socioeconomic and ethnic inequalities in organized colorectal cancer screening participation

Socioeconomic and ethnic inequalities in organized colorectal cancer screening participation Socioeconomic and ethnic inequalities in organized colorectal cancer screening participation C.M. de Klerk 1, S. Gupta 2, E. Dekker 1, M.L. Essink-Bot 3 1) Department of Gastroenterology and Hepatology,

More information

Occult small bowel bleeding - Video capsule first

Occult small bowel bleeding - Video capsule first Occult small bowel bleeding - Video capsule first Prof. Joseph Sung The Chinese University of Hong Kong Disclosure of Potential Conflict of Interest: Nothing to Disclose Obscure Gastrointestinal Bleeding

More information

Screening and Primary prevention of Colorectal Cancer: a Review of sex-specific and site-specific differences

Screening and Primary prevention of Colorectal Cancer: a Review of sex-specific and site-specific differences Original Article Screening and Primary prevention of Colorectal Cancer: a Review of sex-specific and site-specific differences J Med Screen 20(3) 125 148! The Author(s) 2013 Reprints and permissions: sagepub.co.uk/journalspermissions.nav

More information

Predictors of Repeat Participation in the NHS Bowel Cancer Screening Programme

Predictors of Repeat Participation in the NHS Bowel Cancer Screening Programme Lo, SH; Halloran, S; Snowball, J; Seaman, H; Wardle, J; von Wagner, C; (2015) Predictors of repeat participation in the NHS bowel cancer screening programme. Br J Cancer, 112 (1) 199-206. 10.1038/bjc.2014.569.

More information

EXPERT WORKING GROUP Surveillance after neoplasia removal. Meeting Chicago, May 5th 2017 Chair: Rodrigo Jover Uri Ladabaum

EXPERT WORKING GROUP Surveillance after neoplasia removal. Meeting Chicago, May 5th 2017 Chair: Rodrigo Jover Uri Ladabaum EXPERT WORKING GROUP Surveillance after neoplasia removal Meeting Chicago, May 5th 2017 Chair: Rodrigo Jover Uri Ladabaum AIM To improve the quality of the evidences we have regarding post- polypectomy

More information

FIT Laboratory update

FIT Laboratory update FIT Laboratory update Sally C Benton Consultant Clinical Biochemist, Berkshire and Surrey Pathology Services (BSPS) Director, Bowel Cancer Screening Southern Hub Date: 26 th February 2019 February 2017.

More information

Dr Graeme Suthers: The genetic basis of cancer

Dr Graeme Suthers: The genetic basis of cancer Dr Graeme Suthers: The genetic basis of cancer Dr Suthers is the head of the Familial Cancer Unit at the Women s and Children s hospital. He will begin the evening with an introduction to cancer and its

More information

A Blood-Based Biomarker for screening for Colorectal Cancer

A Blood-Based Biomarker for screening for Colorectal Cancer WEO CRC SC Meeting Hong Kong, 25 Sep, 2017 A Blood-Based Biomarker for screening for Colorectal Cancer K.G. YEOH MBBS, MMed, FRCP (London), FRCP (Glasg), FAMS Dean, School of Medicine, National University

More information

Achieving 80% by 2018: Working Together Can Get Us There. Zachary Gregg, MD Sentara Martha Jefferson April 18, 2016

Achieving 80% by 2018: Working Together Can Get Us There. Zachary Gregg, MD Sentara Martha Jefferson April 18, 2016 Achieving 80% by 2018: Working Together Can Get Us There Zachary Gregg, MD Sentara Martha Jefferson April 18, 2016 1 Prostate 21% Lung & bronchus 14% Colon & rectum 8% Urinary bladder 7% Melanoma of skin

More information

BACKGROUND. Fecal immunochemical tests (FIT) are an advanced fecal occult. METHODS. Individuals sampled consecutive stools, at home, with both FIT and

BACKGROUND. Fecal immunochemical tests (FIT) are an advanced fecal occult. METHODS. Individuals sampled consecutive stools, at home, with both FIT and 2152 Comparison of a Brush-Sampling Fecal Immunochemical Test for Hemoglobin With a Sensitive Guaiac-Based Fecal Occult Blood Test in Detection of Colorectal Neoplasia Alicia Smith 1,2 Graeme P. Young,

More information

GENERAL PRACTITIONERS IN THE 1ST LINE OF CANCER PREVENTION

GENERAL PRACTITIONERS IN THE 1ST LINE OF CANCER PREVENTION GENERAL PRACTITIONERS IN THE 1ST LINE OF CANCER PREVENTION Bohumil Seifert Dpt. Of General Practice 1st Faculty of Medicine Charles University in Prague May, 29, 2015 European Colorectal Cancer Days, Brno

More information

Dr Alasdair Patrick. Dr Nagham Al-Mozany. 9:45-10:10 Where Are We Up To With Bowel Cancer Screening?

Dr Alasdair Patrick. Dr Nagham Al-Mozany. 9:45-10:10 Where Are We Up To With Bowel Cancer Screening? Dr Alasdair Patrick Gastroenterologist and General Physician Middlemore Hospital Auckland Dr Nagham Al-Mozany Colorectal Surgeon Auckland City Hospital Clinical Senior Lecturer University of Auckland 9:45-10:10

More information

Chicago th Meeting of the Expert Working Group (EWG) FIT for Screening MEETING REPORT

Chicago th Meeting of the Expert Working Group (EWG) FIT for Screening MEETING REPORT Chicago 2014 5 th Meeting of the Expert Working Group (EWG) FIT for Screening Expert Working Group (EWG) founding members: Friday, 2 May 2014: 08:30 11:30 MEETING REPORT * * * * * Jim Allison, University

More information

Estimates of complications and clinically significant findings in screening and surveillance colonoscopy

Estimates of complications and clinically significant findings in screening and surveillance colonoscopy Oregon Health & Science University OHSU Digital Commons Scholar Archive February 2011 Estimates of complications and clinically significant findings in screening and surveillance colonoscopy J. Lucas Williams

More information

Performance measures in three rounds of the English bowel cancer screening pilot

Performance measures in three rounds of the English bowel cancer screening pilot < An additional appendix is published online only. To view this files please visit the journal online (http://gut.bmj.com). 1 Cancer Screening Evaluation Unit, Section of Epidemiology, Institute of Cancer

More information

Population-based colorectal cancer screening by fecal immunochemical testing over multiple rounds van der Vlugt, M.

Population-based colorectal cancer screening by fecal immunochemical testing over multiple rounds van der Vlugt, M. UvA-DARE (Digital Academic Repository) Population-based colorectal cancer screening by fecal immunochemical testing over multiple rounds van der Vlugt, M. Link to publication Citation for published version

More information

When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool

When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool When is a programmed follow-up meaningful and how should it be done? Professor Alastair Watson University of Liverpool Adenomas/Carcinoma Sequence Providing Time for Screening Normal 5-20 yrs 5-15 yrs

More information

EVALUATION OF QUANTITATIVE DETECTION OF FECAL HUMAN HAEMOGLOBIN FOR COLORECTAL CANCER SCREENING

EVALUATION OF QUANTITATIVE DETECTION OF FECAL HUMAN HAEMOGLOBIN FOR COLORECTAL CANCER SCREENING EVALUATION OF QUANTITATIVE DETECTION OF FECAL HUMAN HAEMOGLOBIN FOR COLORECTAL CANCER SCREENING Kocna P., Vaníčková Z., Kovářová J., Krechler T., Kohout P., Beneš Z., Granátová J. Institute of Clinical

More information

Prevention of Bowel Cancer: which patients do I send for colonoscopy?

Prevention of Bowel Cancer: which patients do I send for colonoscopy? Prevention of Bowel Cancer: which patients do I send for colonoscopy? Dr Chris Groves Consultant Gastroenterologist and Honorary Senior Lecturer St George s Hospital and Medical School Director, SW London

More information

FIT for symptomatic patients. Facilitator name

FIT for symptomatic patients. Facilitator name FIT for symptomatic patients Facilitator name Context colorectal cancer Colorectal cancer in the UK 41,804 new cases in 2015 15,903 deaths in 2014 Fourth most common cancer Second most common cause of

More information

Colorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005

Colorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005 Colorectal Cancer Screening: Cost-Effectiveness and Adverse events October, 2005 David Lieberman MD Chief, Division of Gastroenterology Oregon Health and Science University Portland VAMC Portland, Oregon

More information

Dr Katie Elliott CRUK strategic GP Macmillan GP with NE &C Learning disability Network Assistant Clinical Lead Northern Cancer Alliance

Dr Katie Elliott CRUK strategic GP Macmillan GP with NE &C Learning disability Network Assistant Clinical Lead Northern Cancer Alliance FIT for symptomatic patients Dr Katie Elliott CRUK strategic GP Macmillan GP with NE &C Learning disability Network Assistant Clinical Lead Northern Cancer Alliance AIMS Review National advice Consider

More information

Friday, 20 May 2016: 10:15 12:00 MEETING REPORT * * * * *

Friday, 20 May 2016: 10:15 12:00 MEETING REPORT * * * * * San Diego 2016 9 th Meeting of the Expert Working Group (EWG) FIT for Screening Expert Working Group (EWG) founding members: Friday, 20 May 2016: 10:15 12:00 MEETING REPORT * * * * * Jim Allison, University

More information

Fecal immunochemical testing results and characteristics of colonic lesions

Fecal immunochemical testing results and characteristics of colonic lesions Original article 111 Fecal immunochemical testing results and characteristics of colonic lesions Authors Sascha C. van Doorn 1, Inge Stegeman 2, An K. Stroobants 3, Marco W. Mundt 4, Thomas R. de Wijkerslooth

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Holme Ø, Løberg M, Kalager M, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA. doi:10.1001/jama.2014.8266

More information

Objectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background

Objectives. Definitions. Colorectal Cancer Screening 5/8/2018. Payam Afshar, MS, MD Kaiser Permanente, San Diego. Colorectal cancer background Colorectal Cancer Screening Payam Afshar, MS, MD Kaiser Permanente, San Diego Objectives Colorectal cancer background Colorectal cancer screening populations Colorectal cancer screening modalities Colonoscopy

More information

Colorectal cancer screening: strategies to select populations with moderate risk for disease

Colorectal cancer screening: strategies to select populations with moderate risk for disease 1130-0108/2009/101/12/855-860 REVISTA ESPAÑOLA DE ENFERMEDADES DIGESTIVAS Copyright 2009 ARÁN EDICIONES, S. L. REV ESP ENFERM DIG (Madrid) Vol. 101. N. 12, pp. 855-860, 2009 Colorectal cancer screening:

More information

Is aspirin ready for colorectal cancer chemoprevention and adjuvant therapy?

Is aspirin ready for colorectal cancer chemoprevention and adjuvant therapy? Is aspirin ready for colorectal cancer chemoprevention and adjuvant therapy? Robert Benamouzig Service de Gastroentérologie Hôpital Avicenne Bobigny, France Aspirin and Colorectal carcinogenesis Aspirin

More information

Colorectal Cancer Screening and Perceived Disgust: The Importance of the Ick Factor in Faecal Occult Blood Test Uptake

Colorectal Cancer Screening and Perceived Disgust: The Importance of the Ick Factor in Faecal Occult Blood Test Uptake Research Article imedpub Journals http://www.imedpub.com Colorectal Cancer: Open Access Colorectal Cancer Screening and Perceived Disgust: The Importance of the Ick Factor in Faecal Occult Blood Test Uptake

More information

Heather Hampel, MS, CGC Professor, Division of Human Genetics

Heather Hampel, MS, CGC Professor, Division of Human Genetics Familial, Hereditary, and Early Age Onset Colorectal Cancer: A Module Designed to Assist Primary Care Clinician s in the Identification of Individuals at Increased Risk and Facilitate Earliest Possible

More information

Colon Cancer Screening. A Provider Opinion Survey

Colon Cancer Screening. A Provider Opinion Survey Colon Cancer Screening A Provider Opinion Survey 1. Background Information What is colon cancer? Who needs to be screened? Colorectal Cancer» Presence of abnormal cells in the colon or rectum that divide

More information

FREQUENTLY ASKED QUESTIONS

FREQUENTLY ASKED QUESTIONS FREQUENTLY ASKED QUESTIONS What is CRC? CRC (CRC) is cancer of the large intestine (colon), the lower part of the digestive system. Rectal cancer is cancer of the last several inches of the colon. Together,

More information

Mr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer

Mr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer Mr Chris Wakeman General Surgeon University of Otago, Christchurch 12:15-12:40 Management of Colorectal Cancer Bowel cancer Chris Wakeman Colorectal Surgeon Christchurch Sam Simon (Simpsons) Elizabeth

More information

Increasing Colorectal Cancer Screening in Wyoming. Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program

Increasing Colorectal Cancer Screening in Wyoming. Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program Increasing Colorectal Cancer Screening in Wyoming Allie Bain, MPH Outreach & Education Supervisor Wyoming Integrated Cancer Services Program Overview What is colorectal cancer? What are risk factors for

More information

Improving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC)

Improving Outcomes in Colorectal Cancer: The Science of Screening. Colorectal Cancer (CRC) Improving Outcomes in Colorectal Cancer: The Science of Screening Tennessee Primary Care Association October 23, 2014 Durado Brooks, MD, MPH Director, Prostate and Colorectal Cancers Colorectal Cancer

More information

In What Asia-Pacific Populations is CRC Screening Justified?

In What Asia-Pacific Populations is CRC Screening Justified? WEO CRC SC Meeting APDW Taipei, December 3, 2015 In What Asia-Pacific Populations is CRC Screening Justified? K.G. YEOH MBBS, MMed, FRCP (London), FRCP (Glasg), FAMS Dean, NUS School of Medicine, Senior

More information

Time to Colonoscopy After a Positive Fecal Test and Risk of Colorectal Cancer Outcomes

Time to Colonoscopy After a Positive Fecal Test and Risk of Colorectal Cancer Outcomes Time to Colonoscopy After a Positive Fecal Test and Risk of Colorectal Cancer Outcomes Douglas Corley MD, PhD Kaiser Permanente, Northern California For Corley DA, Jensen CD, Quinn VP, Doubeni CA, Zauber

More information

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines

Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines Alberta Colorectal Cancer Screening Program (ACRCSP) Post Polypectomy Surveillance Guidelines June 2013 ACRCSP Post Polypectomy Surveillance Guidelines - 2 TABLE OF CONTENTS Background... 3 Terms, Definitions

More information

Engaging Primary Care in bowel screening

Engaging Primary Care in bowel screening Engaging Primary Care in bowel screening GP good practice guide for Wales December 2018 Together we will beat cancer Contents Background 3 The FIT screening pathway in Wales 4 The role of GP practices

More information

Colorectal Cancer Prevention Hospital Universitário São Paulo University

Colorectal Cancer Prevention Hospital Universitário São Paulo University Colorectal Cancer Prevention Hospital Universitário São Paulo University GENERAL STRATEGY AND RESULTS Dr Luis Masúo Maruta Dr. Marcelo Rodrigues Borba Hospital Universitário São Paulo University Hospital

More information